PHAT · Phathom Pharmaceuticals, Inc.
$9.58
+0.40 (+4.36%)
At close · Aug 14
Market Cap
$775.03M
Shares
80.90M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$9.58
Open$9.13
Day$9.08–9.59
52W close$8.23–18.08
Avg vol 30d1.6M
Short int13.3M · 16.5% float · 8.7d
Short vol35%
Last earningsJul 30, 2026
DataJan 2020–Aug 2026
Filing10-Q · Jul 30
Up next
Next earnings call
Oct 26, 2026
Est · unconfirmed
· in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Jul 30, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−23%
below
Price vs 50-day avg
−8%
below
RSI (14)
47
neutral
MACD trend
Positive
52-week position
14%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−12%
trailing
6-month return
−16%
trailing
YTD return
−42%
this year
Relative strength
−30%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $10 › 200d $12 — 200d above 50d
Institutional flow
Distributing
-7% holders QoQ · +22 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
16.47% of float · ▲ +9.9% MoM · 8.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
163 holders — mid 3-yr range
Squeeze score
69
elevated · 0–100
Fundamentals
Revenue growth
+217%
Y/Y
Gross margin
87%
expanding
EPS growth
+43%
Y/Y
Free cash flow
$-167.0M
Balance sheet
$79.1M
net debt
Quant / Vol
risk profile
Volatility
65%
annualized · 1-yr
Max drawdown
−54%
past year
ATR
6.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Jun 30, 2026
Revenue
· full year 2026
$310M – $325M
Prior guidance
period ended
· from the Earnings Call filed Sep 30, 2025
Full year revenue
· full year 2025
$170M – $175M
Non-GAAP operating expenses
· full year 2025
$280M – $290M
Gross to net
· fourth quarter
55% – 60%
Non-GAAP operating expenses (CashOpex)
· fourth quarter 2025
up to $55M
Operating expenses excluding stock-based compensation
· fourth quarter
up to $55M
Guided vs delivered
· last 1 settled
Full year revenue
full year 2025
guided $170M – $175M
$175.11M
Beat +1.5%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−23%
Bearish
Price vs 50-day avg
−8%
Bearish
RSI (14)
47
Neutral
MACD trend
Positive
Bullish
52-week position
14%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $10 › 200d $12 — 200d above 50d
Institutional flow
Distributing
-7% holders QoQ · +22 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
16.47% of float · ▲ +9.9% MoM · 8.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
163 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $8
Now $10 · 14%
Range high $18
vs 200-day avg -23%
vs 50-day avg -8%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Covered prescriptions | 209,000 | second quarter 2026 | — |
| Non-GAAP adjusted net loss non-GAAP | $0.1M | second quarter 2026 | — |
|
|
|||
| Non-GAAP operating expenses non-GAAP | $56.4M | second quarter 2026 | — |
|
|
|||
| Stock-based compensation | $6.7M | second quarter 2026 | — |
| Total VOQUEZNA prescriptions filled | 325,000 | second quarter 2026 | — |
| Covered prescriptions year-over-year growth | 91% | first quarter 2026 | — |
| Total VOQUEZNA prescriptions filled in the first quarter | 268,000 | first quarter 2026 | — |
| Total VOQUEZNA prescriptions filled to date | 1.35M | as of April 17, 2026 | — |
| Covered prescriptions growth | 21% | the fourth quarter | — |
| Net cash usage | 5.2M | the fourth quarter | — |
| VOQUEZNA total prescriptions filled | 1.1M | as of February 13, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PHAT
this stock
Phathom Pharmaceuticals, Inc.
|
$775.03M | -42.3% | +216.9% | — | 16.5% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +14.4% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.19B | +11.6% | +46.2% | 29.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.1% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PHAT | +12.1% | -12.4% | -15.7% | +9.5% | -42.3% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +11.7% | -16.9% | -29.5% | +5.6% | -56.1% |
Key facts
CIK
1783183
CUSIP
71722W107
13F (30d)
155 filings
152 filers
Visit website
Investor relations